A recent clinical trial with advanced ovarian cancer patients and nivolumab in combination with varlilumab, found one of eight patients experienced dose limiting liver and renal toxicity, though overall treatment was correlated with increases in CD8+ T-cell infiltration and decreases in circulating Tregs [228]. Here, CD8A is linked to ovarian cancer.